China State FDA

The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.

The real-time PCR-based test is designed to identify EGFR mutations in circulating tumor DNA in plasma samples.

The kits cover the primary genetic targets currently used for assessing the compatibility of  hematopoietic cell donors with recipients.

Company highlights during the first half of 2017 include China approval for Novaprep for non-gynecological cancer testing, and a €3 million private financing round. 

Through the deal, the companies aim to bring new next-generation sequencing-based oncology diagnostic kits to the Chinese market.

BGISEQ-50

The new BGISEQ-50, a smaller version of the BGISEQ-500, will have research and clinical applications, and BGI plans to register it with the CFDA, too.

China-based Burning Rock will develop cancer diagnostics for Chinese patients based on the Agilent SureSelect target enrichment system.

The diagnostic, a real-time PCR kit for breast cancer stratification, is being reviewed under a special process for the approval of innovative products.

Only about 5 to 6 percent of women in China, mostly in urban areas, currently obtain NIPT, but their number is expected to increase quickly in coming years.

The country recently implemented a pilot program issuing licenses to hospitals to run NGS tests for NIPT, PGS/PGD, cancer, and genetic disease.

Pages

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.